Agios Pharmaceuticals, Inc.
AGIO
$29.20
-$1.03-3.41%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 48.03% | 36.26% | 30.57% | 25.96% | 36.07% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 48.03% | 36.26% | 30.57% | 25.96% | 36.07% |
| Cost of Revenue | 13.24% | 13.54% | 5.21% | 3.41% | 2.36% |
| Gross Profit | -8.51% | -10.74% | -2.35% | -0.96% | 0.97% |
| SG&A Expenses | 14.99% | 28.47% | 39.12% | 36.51% | 30.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.83% | 18.31% | 15.13% | 13.02% | 10.50% |
| Operating Income | -10.90% | -16.86% | -13.94% | -12.05% | -8.75% |
| Income Before Tax | -157.63% | -156.38% | 290.26% | 301.42% | 303.92% |
| Income Tax Expenses | -102.30% | -116.71% | -- | -- | -- |
| Earnings from Continuing Operations | -161.27% | -159.51% | 278.14% | 288.87% | 291.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -161.27% | -159.51% | 278.14% | 288.87% | 291.35% |
| EBIT | -10.90% | -16.86% | -13.94% | -12.05% | -8.75% |
| EBITDA | -11.16% | -17.20% | -14.33% | -12.40% | -9.15% |
| EPS Basic | -160.23% | -158.99% | 276.72% | 285.73% | 286.86% |
| Normalized Basic EPS | -9.25% | -11.11% | -6.01% | -5.29% | -3.26% |
| EPS Diluted | -162.50% | -161.24% | 269.94% | 278.75% | 279.89% |
| Normalized Diluted EPS | -9.91% | -11.80% | -5.40% | -4.66% | -2.64% |
| Average Basic Shares Outstanding | 2.05% | 2.03% | 2.01% | 2.05% | 2.08% |
| Average Diluted Shares Outstanding | 1.38% | 1.36% | 2.67% | 2.72% | 2.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |